Guided Therapeutics (GTHP) Accumulated Expenses (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Accumulated Expenses data on file, last reported at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses rose 69.93% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (up 69.93% YoY), and the FY2025 full-year result was $1.7 million, up 69.93% from the prior year.
• Accumulated Expenses grew to $1.7 million in Q4 2025, from $8000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $4.9 million in Q1 2021 to a low of $7000.0 in Q3 2023.
• A 5-year average of $975347.2 and a median of $991000.0 in 2023 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 4985.71% in 2023, while the deepest fall reached 99.33% in 2023.
• Tracing GTHP's Accumulated Expenses over 5 years: stood at $1.8 million in 2021, then plunged by 98.81% to $21000.0 in 2022, then soared by 4985.71% to $1.1 million in 2023, then fell by 5.34% to $1.0 million in 2024, then soared by 69.93% to $1.7 million in 2025.
• Business Quant data shows GTHP's Accumulated Expenses at $1.7 million in Q4 2025, $8000.0 in Q3 2025, and $8000.0 in Q2 2025.